Is GlobalFoundries On The Verge Of A Breakout?
GLOBALFOUNDRIES Inc. (NASDAQ:GFS) is as a semiconductor foundry whose chips…
Sell
43
WBA Quote, Financials, Valuation and Earnings
Last price:
$11.24
Seasonality move
:
2.87%
Day range:
$11.19 - $11.25
52-week range:
$8.08 - $18.17
Dividend yield:
8.89%
P/E ratio:
--
P/S ratio:
0.06x
P/B ratio:
1.37x
Volume:
3.7M
Avg. volume:
11M
1-year change:
-38.12%
Market cap:
$9.7B
Revenue:
$147.7B
EPS (TTM):
-$6.69
Analysts' Opinion
-
Consensus RatingWalgreens Boots Alliance has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 11 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $12.29, Walgreens Boots Alliance has an estimated upside of 9.27% from its current price of $11.25.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $11.25.
Fair Value
-
According to the consensus of 14 analysts, Walgreens Boots Alliance has 9.27% upside to fair value with a price target of $12.29 per share.
WBA vs. S&P 500
-
Over the past 5 trading days, Walgreens Boots Alliance has underperformed the S&P 500 by -2.49% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Walgreens Boots Alliance does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Walgreens Boots Alliance has grown year-over-year revenues for 9 quarters straight. In the most recent quarter Walgreens Boots Alliance reported revenues of $38.6B.
Earnings Growth
-
Walgreens Boots Alliance has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Walgreens Boots Alliance reported earnings per share of -$3.30.
Enterprise value:
16.8B
EV / Invested capital:
1.10x
Price / LTM sales:
0.06x
EV / EBIT:
--
EV / Revenue:
0.11x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
29.35x
Price / Operating cash flow:
17.02x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$26.4B
Return On Assets:
-7.28%
Net Income Margin (TTM):
-3.8%
Return On Equity:
-46.98%
Return On Invested Capital:
-27.39%
Operating Margin:
-5.07%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-02-28 | 2024-02-28 | 2025-02-28 | 2024-02-28 | 2025-02-28 | |
| Income Statement | ||||||
| Revenue | $133.3B | -- | $151.9B | -- | $38.6B | |
| Gross Profit | $27B | -- | $26.4B | -- | $6.9B | |
| Operating Income | -$7.4B | -- | -$2.8B | -- | -$2B | |
| EBITDA | -$3B | -- | -$2.6B | -- | -$3.5B | |
| Diluted EPS | -$3.65 | -- | -$6.69 | -- | -$3.30 | |
| Period Ending | 2021-02-28 | 2022-02-28 | 2023-02-28 | 2024-02-28 | 2025-02-28 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $26.1B | $16.8B | $17.7B | -- | $16.2B | |
| Total Assets | $90.9B | $92.7B | $100.5B | -- | $70.2B | |
| Current Liabilities | $31.2B | $22.7B | $28.2B | -- | $26.6B | |
| Total Liabilities | $69.3B | $61.8B | $70.9B | -- | $63B | |
| Total Equity | $21.6B | $30.9B | $29.6B | -- | $7.3B | |
| Total Debt | $16.2B | $13.3B | $13B | -- | $8B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-02-28 | 2024-02-28 | 2025-02-28 | 2024-02-28 | 2025-02-28 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $3B | -- | $1.6B | -- | -$199M | |
| Cash From Investing | -$2.5B | -- | $1.3B | -- | $418M | |
| Cash From Financing | -$502M | -- | -$2.4B | -- | -$288M | |
| Free Cash Flow | $982M | -- | $571M | -- | -$418M | |
WBA
Sector
Market Cap
$9.7B
$257.5M
Price % of 52-Week High
61.92%
75.86%
Dividend Yield
8.89%
0%
Shareholder Yield
12.44%
2.91%
1-Year Price Total Return
-38.12%
-13.43%
Beta (5-Year)
0.773
0.395
Dividend yield:
8.89%
Annualized payout:
$1.23
Payout ratio:
-14.95%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$11.25
200-day SMA
Buy
Level
$10.15
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$11.09
Relative Strength Index (RSI14)
Buy
Level
56.56
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-40.3509
50-day SMA
Buy
Level
$11.06
MACD (12, 26)
Buy
Level
0.09
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.6081)
Sell
CA Score
(Annual)
Level (-2.0171)
Buy
Beneish M-Score
(Annual)
Level (-3.454)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.4585)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Walgreens Boots Alliance is one of the largest retail pharmacy chains in the US, with over 8,000 locations. Nearly three quarters of Americans live within five miles of a Walgreens location. Roughly two thirds of revenue is generated from prescription drug sales; Walgreens makes up 20% of total prescription revenue in the US. Walgreens also generates sales from retail products (general wellness consumables and its own branded merchandise), European drug wholesale, and healthcare. With more locations incorporating additional services like Health Corner and Village Medical, Walgreens creates an omnichannel experience for patients and positions itself as a one-stop healthcare provider.
Stock Forecast FAQ
In the current month, WBA has received 2 Buy ratings 11 Hold ratings, and 1 Sell ratings. The WBA average analyst price target in the past 3 months is $12.29.
-
Where Will Walgreens Boots Alliance Stock Be In 1 Year?
According to analysts, the consensus estimate is that Walgreens Boots Alliance share price will rise to $12.29 per share over the next 12 months.
-
What Do Analysts Say About Walgreens Boots Alliance?
Analysts are divided on their view about Walgreens Boots Alliance share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Walgreens Boots Alliance is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Walgreens Boots Alliance's Price Target?
The price target for Walgreens Boots Alliance over the next 1-year time period is forecast to be $12.29 according to 14 Wall Street analysts, 2 of them rate the stock a Buy, 1 rates the stock a Sell, and 11 analysts rate the stock a Hold.
-
Is WBA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Walgreens Boots Alliance is a Hold. 11 of 14 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of WBA?
You can purchase shares of Walgreens Boots Alliance via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Walgreens Boots Alliance shares.
-
What Is The Walgreens Boots Alliance Share Price Today?
Walgreens Boots Alliance was last trading at $11.24 per share. This represents the most recent stock quote for Walgreens Boots Alliance. Yesterday, Walgreens Boots Alliance closed at $11.25 per share.
-
How To Buy Walgreens Boots Alliance Stock Online?
In order to purchase Walgreens Boots Alliance stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Dick’s Sporting Goods Buying Foot Locker Smart?
Last week, Dick’s Sporting Goods (NYSE:DKS) announced that it would…
Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Alerts
Buy
55
RGC alert for May 21
Regencell Bioscience Holdings [RGC] is up 31.16% over the past day.
Buy
64
AKRO alert for May 21
Akero Therapeutics [AKRO] is up 24.59% over the past day.
Buy
76
AGYS alert for May 21
Agilysys [AGYS] is up 22.13% over the past day.
